Cargando…

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

BACKGROUND: Maturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV) particle maturation, the structural rearrangement required to form infectious virus particles. This rearrangement is triggered by the ordered cleavage of the precursor Gag p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fun, Axel, van Maarseveen, Noortje M, Pokorná, Jana, Maas, Renée EM, Schipper, Pauline J, Konvalinka, Jan, Nijhuis, Monique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184055/ https://www.ncbi.nlm.nih.gov/pubmed/21864346 http://dx.doi.org/10.1186/1742-4690-8-70

Ejemplares similares

Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity
por: van Maarseveen, Noortje M, et al.
Publicado: (2012)

Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor
por: Allaway, Graham P
Publicado: (2006)

A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism
por: Nijhuis, Monique, et al.
Publicado: (2007)

Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice
por: Stoddart, Cheryl A., et al.
Publicado: (2007)

Current and Novel Inhibitors of HIV Protease
por: Pokorná, Jana, et al.
Publicado: (2009)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
por: Nijhuis, Monique
Publicado: (2011)

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat
por: Adamson, Catherine S, et al.
Publicado: (2010)

The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles
por: Nguyen, Albert T, et al.
Publicado: (2011)

Preservation of HIV-1 Gag Helical Bundle Symmetry by Bevirimat Is Central to Maturation Inhibition
por: Pak, Alexander J., et al.
Publicado: (2021)

Predicting Bevirimat resistance of HIV-1 from genotype
por: Heider, Dominik, et al.
Publicado: (2010)

Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process
por: Adamson, Catherine S.
Publicado: (2012)

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates
por: Ray, Neelanjana, et al.
Publicado: (2017)

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance
por: Fun, Axel, et al.
Publicado: (2018)

New Phosphorus Analogs of Bevirimat: Synthesis, Evaluation of Anti-HIV-1 Activity and Molecular Docking Study
por: Chrobak, Elwira, et al.
Publicado: (2019)

Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis
por: Messiaen, Peter, et al.
Publicado: (2013)

Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation
por: Humpolíčková, Jana, et al.
Publicado: (2018)

Interdependence of Inhibitor Recognition in HIV-1 Protease
por: Paulsen, Janet L., et al.
Publicado: (2017)

Thermodynamic characterization of the peptide assembly inhibitor binding to HIV-1 capsid protein
por: Kozisek, Milan, et al.
Publicado: (2013)

HIV-1 Maturation: Lessons Learned from Inhibitors
por: Kleinpeter, Alex B., et al.
Publicado: (2020)

Classification of HIV-1 Protease Inhibitors by Machine Learning Methods
por: Li, Yang, et al.
Publicado: (2018)

Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors
por: Okafor, Sunday N., et al.
Publicado: (2023)

Inhibitor and Substrate Binding Induced Stability of HIV-1 Protease against Sequential Dissociation and Unfolding Revealed by High Pressure Spectroscopy and Kinetics
por: Ingr, Marek, et al.
Publicado: (2015)

Human Immunodeficiency Virus gag and protease: partners in resistance
por: Fun, Axel, et al.
Publicado: (2012)

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
por: Dunn, David T., et al.
Publicado: (2018)

Structural basis of HIV-1 maturation inhibitor binding and activity
por: Sarkar, Sucharita, et al.
Publicado: (2023)

Alteration of HIV epitope processing and presentation by HIV protease inhibitors
por: Kourjian, G, et al.
Publicado: (2012)

Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor
por: Schimer, Jiří, et al.
Publicado: (2015)

Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers
por: Dybowski, J Nikolaj, et al.
Publicado: (2011)

Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children
por: Gonzalez-Tome, M Isabel, et al.
Publicado: (2008)

Virtual Screening of Indonesian Herbal Database as HIV-1 Protease Inhibitor
por: Yanuar, Arry, et al.
Publicado: (2014)

Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity
por: Windsor, Ian W., et al.
Publicado: (2015)

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors
por: Monica, Gabriele La, et al.
Publicado: (2021)

Accurate Prediction of Inhibitor Binding to HIV-1 Protease Using CANDOCK
por: Falls, Zackary, et al.
Publicado: (2022)

Role of Gag in HIV Resistance to Protease Inhibitors
por: Clavel, François, et al.
Publicado: (2010)

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance
por: Babrzadeh, Farbod, et al.
Publicado: (2013)

Structural and Functional Insights into the HIV-1 Maturation Inhibitor Binding Pocket
por: Waki, Kayoko, et al.
Publicado: (2012)

Identification of potent maturation inhibitors against HIV-1 clade C
por: Timilsina, Uddhav, et al.
Publicado: (2016)

An Assay to Monitor HIV-1 Protease Activity for the Identification of Novel Inhibitors in T-Cells
por: Hilton, Brett J., et al.
Publicado: (2010)

Enhancement of Probe Signal for Screening of HIV-1 Protease Inhibitors in Living Cells
por: Yao, Huantong, et al.
Publicado: (2012)

Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors
por: Wright, David W., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q1grb06sieoauj23huvcijednc